ADAG - צמיחת מכירות משנה לשנה (TTM) Adagene

Adagene is developing an innovative CTLA-4 inhibitor with support from Sanofi. The YoY sales growth over the last four quarters on the GURU.Markets chart visualizes this trend, where 8871.00 indicates the current level. The issuer's success relies on antibody safety and partnership goals. The SAFEbody platform enables the creation of targeted oncology therapies that minimize systemic side effects.
Adagene Inc. (ADAG) - פילוחי מדדים ודוחות פיננסיים

The development of the SAFEbody platform and the partnership with Sanofi form the foundation of Adagene (ADAG) cash flows. This metric calculates the percentage deviation of total trailing twelve-month (TTM) revenue relative to the same period last year. This indicator determines the business's ability to scale sales faster than inflationary costs. Growth in this figure confirms the commercial success of the CTLA-4 inhibitor implementation. By analyzing the TTM commercial revenue growth trend, an investor assesses the company's fundamental stability.